Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Brivaracetam
Drug ID BADD_D00297
Description Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760].
Indications and Usage Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
Marketing Status approved; investigational
ATC Code N03AX23
DrugBank ID DB05541
KEGG ID D08879
MeSH ID C482793
PubChem ID 9837243
TTD Drug ID D0CT4D
NDC Product Code 16812-009; 36998-0118; 50474-670; 50474-770; 50474-970; 52076-6268; 28877-0118; 71666-007; 50474-370; 82608-003; 50474-570; 64220-214; 69037-0055; 50474-470; 69766-031; 50474-870
UNII U863JGG2IA
Synonyms brivaracetam | 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide | (2S)-2-((4R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide | 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)- | UCB 34714 | UCB34714 | UCB-34714 | Briviact
Chemical Information
Molecular Formula C11H20N2O2
CAS Registry Number 357336-20-0
SMILES CCCC1CC(=O)N(C1)C(CC)C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Personality change19.05.01.006; 17.02.05.0190.000336%
Petit mal epilepsy17.12.04.0010.000336%-
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.000125%-
Psychotic behaviour19.03.01.003---
Rash23.03.13.0010.003337%-
Respiratory depression22.02.01.010; 17.02.05.0470.000125%-
Respiratory failure22.02.06.002; 14.01.04.0030.000249%
Restlessness17.02.05.021; 19.11.02.0020.000125%
Sedation17.02.04.0050.000909%-
Seizure17.12.03.0010.013362%
Skin reaction23.03.03.013; 10.01.03.0190.000274%-
Sleep disorder19.02.04.0010.000648%-
Somnolence19.02.05.003; 17.02.04.0060.003761%
Speech disorder19.19.02.002; 17.02.08.003; 22.12.03.0270.000125%-
Status epilepticus17.12.03.0050.000311%-
Stress19.06.02.004---
Suicidal ideation19.12.01.0030.001619%
Tearfulness19.15.02.005---
Thrombocytopenia01.08.01.0020.000498%-
Tic19.11.04.001; 17.02.05.0240.000125%-
Tonic convulsion17.12.03.0110.000125%-
Vertigo17.02.12.002; 04.04.01.0030.000125%
General physical health deterioration08.01.03.0180.000125%-
Homicidal ideation19.05.01.0080.000274%-
Balance disorder08.01.03.081; 17.02.02.0070.000398%-
Affect lability19.04.01.001---
Myoclonic epilepsy17.12.03.0070.000249%-
Adverse event08.06.01.0100.000461%-
Mental disorder19.07.01.0020.000336%-
Partial seizures17.12.03.0100.000560%-
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages